Abstract:The process of discovering small molecule drugs involves screening numerous compounds and optimizing the most promising ones, both in vitro and in vivo. However, approximately 90% of these optimized candidates fail during trials due to unexpected toxicity or insufficient efficacy. Current concepts with respect to drug–protein interactions suggest that each small molecule interacts with an average of 6–11 targets. This implies that approved drugs and even discontinued compounds could be repurposed by leveraging their interactions with unintended targets. Therefore, we developed a computational repurposing framework for small molecules, which combines artificial intelligence/machine learning (AI/ML)-based and chemical similarity-based target prediction methods with cross-species transcriptomics information. This repurposing methodology incorporates eight distinct target prediction methods, including three machine learning methods. By using multiple orthogonal methods for a “dataset” composed of 2766 FDA-approved drugs targeting multiple therapeutic target classes, we identified 27,371 off-target interactions involving 2013 protein targets (i.e., an average of around 10 interactions per drug). Relative to the drugs in the dataset, we identified 150,620 structurally similar compounds. The highest number of predicted interactions were for drugs targeting G protein-coupled receptors (GPCRs), enzymes, and kinases with 10,648, 4081, and 3678 interactions, respectively. Notably, 17,283 (63%) of the off-target interactions have been confirmed in vitro. Approximately 4000 interactions had an IC50 of <100 nM for 1105 FDA-approved drugs and 1661 interactions had an IC50 of <10 nM for 696 FDA-approved drugs. Together, the confirmation of numerous predicted interactions and the exploration of tissue-specific expression patterns in human and animal tissues offer insights into potential drug repurposing for new therapeutic applications.

Methods to Profile the Macromolecular Targets of Small Compounds.

Chemical Proteomics to Identify Molecular Targets of Small Compounds

A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

Characterization of Small-Molecule–biomacromolecule Interactions: from Simple to Complex

Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics

Target Identification with Quantitative Activity Based Protein Profiling (ABPP)

Progress of methodology for identifying target protein of natural active small molecules

Recent advances and method development for drug target identification

[Chemical Proteomics and Discovery of Drug Targets].

Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification

Identification and characterization of molecular targets of natural products by mass spectrometry.

Identifying The Proteins To Which Small-Molecule Probes And Drugs Bind In Cells

Label-free target protein characterization for small molecule drugs: recent advances in methods and applications

Identifying the Cellular Targets of Bioactive Small Molecules with Activity-Based Probes.

Artificial Intelligence/Machine Learning-Driven Small Molecule Repurposing via Off-Target Prediction and Transcriptomics

Chemical proteomic mapping of reversible small molecule binding sites in native systems

[The Application of Small Molecule Bioactive Probes in the Identification of Cellular Targets].

An Integrated Structure- and System-Based Framework to Identify New Targets of Metabolites and Known Drugs

Target identification of natural and traditional medicines with quantitative chemical proteomics approaches.

Proteomics in Computer-Aided Drug Design

Systems Pharmacology In Small Molecular Drug Discovery